Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia
MetadataShow full item record
Objective The purpose of this study was to identify the clinical factors associated with time to hCG remission among women with low-risk postmolar GTN. Methods This study included a non-concurrent cohort of 328 patients diagnosed with low-risk postmolar GTN according to FIGO 2002 criteria. Associations of time to hCG remission with history of prior mole, molar histology, time to persistence, use of D&C at persistence, presence of metastatic disease, FIGO score, hCG values at persistence, type of first line therapy and use of multiagent chemotherapy were investigated with both univariate and multivariate analyses. Results Overall median time to remission was 46 days. Ten percent of the patients required multi-agent chemotherapy to achieve hCG remission. Multivariate analysis incorporating the variables significant on univariate analysis confirmed that complete molar histology (HR 1.45), metastatic disease (HR 1.66), use of multi-agent therapy (HR 2.00) and FIGO score (HR 1.82) were associated with longer time to remission. There was a linear relationship between FIGO score and time to hCG remission. Each 1-point increment in FIGO score was associated with an average 17-day increase in hCG remission time (95% CI: 12.5-21.6). Conclusions Complete mole histology prior to GTN, presence of metastatic disease, use of multi-agent therapy and higher FIGO score were independent factors associated with longer time to hCG remission in low-risk GTN. Identifying the prognostic factors associated with time to remission and effective counseling may help improve treatment planning and reduce anxiety in patients and their families. © 2013 Elsevier Inc. All rights reserved.
How to cite this document
Showing items related by title, author, creator and subject.
Epidemiological Report on the Treatment of Patients with Gestational Trophoblastic Disease in 10 Brazilian Referral Centers Results After 12 Years Since International FIGO 2000 Consensus Braga, Antonio; Hartmann Uberti, Elza Maria; Fajardo, Maria do Carmo; Viggiano, Mauricio; Sun, Sue Yazaki; Grillo, Bruno Maurizio; Padilha, Sergio Lunardon; Andrade, Jurandyr Moreira de; Souza, Christiani Bisinoto de; Madi, Jose Mauro et al. (Journal of Reproductive Medicine, 2014) [Artigo]OBJECTIVE: To evaluate treatment of Brazilian patients with gestational trophoblastic disease (GTD).STUDY DESIGN: A retrospective cohort study with analysis of medical reports performed in 10 Brazilian referral centers ...
Lin, Lawrence H.; Maesta, Izildinha ; Laurent, Jessica D. St.; Hasselblatt, Kathleen T.; Horowitz, Neil S.; Goldstein, Donald P.; Quade, Bradley J.; Sun, Sue Y. ; Braga, Antonio; Fisher, Rosemary A. et al. (American Journal Of Obstetrics And Gynecology, 2021) [Artigo]BACKGROUND: MicroRNAs are small noncoding RNAs with important regulatory functions. Although well-studied in cancer, little is known about the role of microRNAs in premalignant disease. Complete hydatidiform moles are ...
Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America Maestá, Izildinha ; De Freitas Segalla Moreira, Marjory ; Rezende-Filho, Jorge; Bianconi, Maria Inés; Jankilevich, Gustavo; Otero, Silvina; Correa Ramirez, Luz Angela ; Sun, Sue Yazaki; Elias, Kevin; Horowitz, Neil et al. (International Journal of Gynecological Cancer, 2020) [Artigo]Background South America has a higher incidence of gestational trophoblastic disease than North America or Europe, but whether this impacts chemotherapy outcomes is unclear. The purpose of this study was to evaluate outcomes ...